Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.400
+0.070 (3.00%)
Apr 24, 2025, 9:29 AM EDT - Market open
Perspective Therapeutics Revenue
In the year 2024, Perspective Therapeutics had annual revenue of $1.45M with 1.39% growth. Perspective Therapeutics had revenue of $234.00K in the quarter ending December 31, 2024, a decrease of -30.56%.
Revenue (ttm)
$1.45M
Revenue Growth
+1.39%
P/S Ratio
103.24
Revenue / Employee
$10,386
Employees
140
Market Cap
177.72M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
CATX News
- 21 hours ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 7 days ago - Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - GlobeNewsWire
- 13 days ago - Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - GlobeNewsWire
- 24 days ago - Perspective Therapeutics to Participate in Upcoming April Investor Conferences - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
- 2 months ago - Perspective Therapeutics to Present at Upcoming March Investor Conferences - GlobeNewsWire